Plastic Waste Transformed Into Parkinson’s Drug in Bioengineering First

Key Takeaways

• Engineered E. coli converts PET into levodopa.
• Process uses seven genes across four enzymatic steps.
• Converted industrial PET and single bottle to drug.
• Algae capture CO2, boosting overall sustainability.
• Potential to upcycle plastic into medicines, chemicals.

Summary

Researchers at the University of Edinburgh have engineered bacteria to transform PET plastic waste into levodopa, a primary treatment for Parkinson’s disease. By inserting a seven‑gene, four‑step biosynthetic pathway into Escherichia coli, the team converted both industrial PET feedstock and a single consumer bottle into pharmaceutical‑grade l‑DOPA under mild, aqueous conditions. The process also integrates Chlamydomonas algae to capture CO₂ released during synthesis, improving sustainability. This breakthrough demonstrates a viable route to upcycle plastic into high‑value therapeutics and could reshape drug manufacturing.

Pulse Analysis

Plastic pollution remains a global crisis, with billions of tonnes of PET bottles ending in landfills or incinerators each year. Traditional recycling methods often down‑cycle material and still depend on energy‑intensive, fossil‑based chemistry. The emerging field of synthetic biology offers a circular alternative, leveraging microbes to repurpose waste carbon into valuable chemicals. By mimicking natural carbon‑utilization pathways, researchers can transform low‑value waste into high‑value products, aligning environmental stewardship with economic incentives.

The Edinburgh team’s innovation hinges on a meticulously engineered Escherichia coli strain that channels terephthalic acid, the monomer of PET, through a four‑step cascade involving enzymes from Comamonas, Klebsiella pneumoniae, and Fusobacterium nucleatum. Seven heterologous genes orchestrate the conversion of terephthalic acid to protocatechuate, then to catechol, and finally to levodopa via a carbon–carbon bond formation with pyruvate. Integrating the alga Chlamydomonas reinhardtii captures the CO₂ emitted during catechol formation, creating a semi‑closed loop that reduces greenhouse‑gas emissions. Laboratory trials achieved therapeutically relevant levodopa concentrations from both industrial PET flakes and a single discarded bottle, proving scalability from waste streams to drug‑grade output.

Beyond Parkinson’s therapy, this platform could democratize the production of a range of pharmaceuticals, flavors, fragrances, and industrial chemicals traditionally derived from petroleum. By decoupling drug synthesis from volatile oil markets, manufacturers gain supply‑chain resilience while contributing to waste mitigation. However, commercial deployment will require optimization of yield, downstream purification, and regulatory approval pathways. If these hurdles are overcome, bio‑upcycling of plastic could become a cornerstone of sustainable manufacturing, reshaping both the plastics and pharmaceutical industries toward a truly circular economy.